Recent Investment Analysts’ Ratings Updates for Werewolf Therapeutics (HOWL)

A number of firms have modified their ratings and price targets on shares of Werewolf Therapeutics (NASDAQ: HOWL) recently:

• 5/24/2024 – Werewolf Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 5/6/2024 – Werewolf Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
• 5/6/2024 – Werewolf Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
• 5/6/2024 – Werewolf Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 4/3/2024 – Werewolf Therapeutics is now covered by analysts at JMP Securities. They set a “mkt outperform” rating and a $12.00 price target on the stock.

Werewolf Therapeutics Stock Up 1.7 %

Shares of HOWL traded up $0.09 on Friday, reaching $5.25. The stock had a trading volume of 147,047 shares, compared to its average volume of 223,798. The firm has a market capitalization of $228.17 million, a price-to-earnings ratio of -4.82 and a beta of 0.71. The company has a debt-to-equity ratio of 0.24, a quick ratio of 6.71 and a current ratio of 6.71. The company has a 50-day simple moving average of $5.74 and a 200-day simple moving average of $4.92. Werewolf Therapeutics, Inc. has a 12-month low of $1.57 and a 12-month high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $5.00 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.15%. Sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HOWL. Financial Perspectives Inc raised its stake in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after buying an additional 3,000 shares during the last quarter. Certuity LLC bought a new stake in shares of Werewolf Therapeutics in the 4th quarter worth $39,000. Lighthouse Investment Partners LLC bought a new stake in shares of Werewolf Therapeutics in the 4th quarter worth $87,000. PFM Health Sciences LP increased its holdings in shares of Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after purchasing an additional 909,895 shares in the last quarter. Finally, Denali Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $172,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.